Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TRENDS
TRENDS
- Rituxan Biosimilar Grabs 30% Volume Share in Just 1 Year; Sales Expected to Double in 2019
February 12, 2019
- Drug Formulary Initiatives Moving Beyond Hospitals, Generic Makers Prepping for Regional Lists
January 30, 2019
- Top 10 PHARMA JAPAN Stories in 2018
December 26, 2018
- Generic Industry at Crossroads: Companies Face Pressing Need to Boost Profitability ahead of FY2020
November 28, 2018
- Economic Benefits for Patients, Healthcare Providers Driving Biosimilar Sales Growth as Quality Worries Fade
November 15, 2018
- Hep C Market Shrinking towards Disease Elimination in 2030
October 12, 2018
- “Follow-On” Authorized Generics Gaining Ground in Matured Gx Markets; TS-1 Grabs 80% Share
September 4, 2018
- Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos
August 8, 2018
- As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
July 13, 2018
- Japan Drug Makers Downsizing Parent Companies; Takeda Sheds Over 1,000 People in Divestitures, R&D Rejig
July 3, 2018
- Foreign Players’ Japan Sales Hit Plateau as 11 Firms See Paltry 0.2% Rise; Pfizer, Boehringer Falter
June 20, 2018
- Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
May 31, 2018
- Daiichi Sankyo Espha Sales Double as It Cashes In On Authorized Generic Boom
May 21, 2018
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
- Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
April 3, 2018
- Lilly Japan Joins Top 10 List for 1st Time, Sales Triple in 10 Years on Successive Launches
March 30, 2018
- Merck Deal Could Pave Way for Eisai to Hit 800 Billion Yen Sales Target in FY2020
March 13, 2018
- Countering Abilify Cliff, Otsuka Sees New Drug Franchise Set Stage for Growth Path
February 23, 2018
- With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
February 8, 2018
- Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well
November 22, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…